Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Blood blood.2024025738.

https://doi.org/10.1182/blood.2024025738

Published: 2024

Includes: Supplemental data

Journal Articles

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Blood (2024) 143 (8): 734–737.

https://doi.org/10.1182/blood.2023022937

Published: 2024

Journal Articles

Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience

Florence Lachenal, Pierre Lebreton, Sylvie Bouillie, Gian Matteo Pica, Hassina Aftisse, Laurent Pascal, Lydia Montes, Margaret Macro, Marguerite Vignon, Stephanie Harel, Mariana Fernandez, Chanaz Louni, Antoine Huart, Aurore Perrot

Blood (2023) 142 (Supplement 1): 4739.

https://doi.org/10.1182/blood-2023-180660

Published: 2023

Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Blood (2023) 142 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2023-188655

Published: 2023

Journal Articles

Carfilzomib-Pomalidomide-Dexamethasone in Anti-CD38 Antibodies and Lenalidomide Relapse/Refractory Multiple Myeloma: A Real Life Monocentric Cohort

Pierre-Edouard Debureaux, Alexis Talbot, Nathalie Forgeard, Dikelele Elessa, Floriane Theves, Bruno Royer, Nathalie Desrayaud, Antoine Citerne, Wendy Cuccuini, Laureen Chat, Bertrand Arnulf, Stephanie Harel

Blood (2023) 142 (Supplement 1): 6626.

https://doi.org/10.1182/blood-2023-178082

Published: 2023

Journal Articles

Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies

Blood (2023) 142 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2023-175004

Published: 2023

Journal Articles

Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study

Pierre-Edouard Debureaux, Stephanie Harel, Nathalie Parquet, Virginie Lemiale, Virginie Siguret, Laurie Goubeau, Florence Morin, Bruno Royer, Wendy Cuccuini, Dikelele Elessa, Floriane Theves, Anne Brignier, Elie Azoulay, Bertrand Arnulf, Alexis Talbot

Blood (2022) 140 (Supplement 1): 10046–10047.

https://doi.org/10.1182/blood-2022-156598

Published: 2022

Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Blood (2022) 140 (Supplement 1): 4668–4670.

https://doi.org/10.1182/blood-2022-162682

Published: 2022

Journal Articles

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Blood (2021) 138 (25): 2686–2695.

https://doi.org/10.1182/blood.2021011285

Published: 2021

Includes: Supplemental data

Journal Articles

A Retrospective Study of 67 Inflammatory Waldenström's Macroglobulinemia

Dikelele Elessa, MD, Stephanie Harel, MD, Alexis Talbot, MD, Marion Malphettes, MD, Catherine Thieblemont, MD PhD, Frederic Davi, MD PhD, Odile Maarek, MD, Bertrand Arnulf, MD PhD, Bruno Royer, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137592

Published: 2020

Journal Articles

Overview of the French Practice: Therapeutic Strategies in Patient's First Relapse or Refractory Non IgM AL Amyloidosis

Camille Villesuzanne, Stephanie Harel, Alexis Talbot, MD, Bruno Royer, MD, Naelle Lombion, Fabien Lebras, MD, Mathilde Nouvier, MD, Arnaud Jaccard, MD PhD, Bertrand Arnulf

Blood (2018) 132 (Supplement 1): 3297.

https://doi.org/10.1182/blood-2018-99-114834

Published: 2018

Journal Articles

Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?

Camille Bigenwald, Stephanie Harel, Florian Chevillon, Damien Roos-Weil, Olivier A. Bernard, PhD, Sandy Amorim, MD, Pauline Brice, MD, Ades Lionel, Anne Marie Nloga, Marie Sébert, MD, Thorsten Braun, MD PhD, Virginie Eclache, Catherine Thieblemont, MDPhD, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2886.

https://doi.org/10.1182/blood.V126.23.2886.2886

Published: 2015

Journal Articles

Therapeutic Strategies in Patients with Atypical CML (aCML) and Unclassified MDS/MPN (MDS/MPN-U). a Single Center Report

Thorsten Braun, Aziza Debache, Hervé Roudot, Daniel Lusina, Sylvain Thépot, Virginie Eclache, Antoine Martin, Juliette Soret, Stephanie Harel, Sabine Bréchignac, Charikleia Kelaidi, Lionel Adès, MD PhD, Pierre Fenaux, MD PhD, Claude Gardin

Blood (2014) 124 (21): 5610.

https://doi.org/10.1182/blood.V124.21.5610.5610

Published: 2014

Journal Articles

Impact Of Myelofibrosis (MF) In MDS Treated With Azacitidine (AZA). A Single Center Study

Clemence Legoupil, MD, Marie Sebert, Thorsten Braun, MD, PhD, Claude Gardin, MD, Antoine Martin, MD, Sabine Brechignac, Stephanie Harel, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2013) 122 (21): 1539.

https://doi.org/10.1182/blood.V122.21.1539.1539

Published: 2013

Journal Articles

Abnormal Numbers Of Regulatory T Cell (Tregs) Subsets Are Sigificantly Associated With Adverse Disease Outcome In Lower Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Thorsten Braun, Makoto Miyara, Sabine Brechignac, Stephanie Harel, Sylvain Thepot, Claude Gardin, Guy Gorochov, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2013) 122 (21): 2785.

https://doi.org/10.1182/blood.V122.21.2785.2785

Published: 2013

Journal Articles

Clinical and Biological Features Of Multiple Myeloma (MM) and Monoclonal Gammopathies In Patients With Human Immunodeficiency Virus (HIV) Infection

Alexis Talbot, MD, Laurence Gérard, MD, Raphael Szalat, MD, David Boutboul, Stephanie Harel, MD, Anne Lazareth, Marion Malphettes, MD, PhD, Bouchra Asli, MD, Lionel Galicier, MD, Claire Fieschi, MD, PhD, Eric Oksenhendler, MD, Jean Paul Fermand, MD, Bertrand Arnulf, MD, PhD

Blood (2013) 122 (21): 5348.

https://doi.org/10.1182/blood.V122.21.5348.5348

Published: 2013

Journal Articles

Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML)

Thorsten Braun, Amina Cherait, Celine Berthon, Christophe Willekens, Sophie Park, Marthe Rigal, Sabine Brechignac, Stephanie Harel, Sylvain Thepot, Bruno Quesnel, Claude Gardin, Lionel Ades, Pierre Fenaux, MD, PhD

Blood (2013) 122 (21): 2796.

https://doi.org/10.1182/blood.V122.21.2796.2796

Published: 2013

Journal Articles

Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents

Stephanie Harel, MD, Sophie Bernard, Sylvie Chevret, Regis Peffault de Latour, Lionel Karlin, MD, Marie Robin, MD, PhD, Lionel Ades, MD, PhD, Raphael Szalat, MD, Marion Malphette, Bouchra Asli, MD, Jean Paul Fermand, MD, Bertrand Arnulf, MD, PhD, Gerard Socie

Blood (2012) 120 (21): 2035.

https://doi.org/10.1182/blood.V120.21.2035.2035

Published: 2012

Journal Articles

Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

Bertrand Arnulf, MD, PhD, Anne Lazareth, Jean Soulier, MD, PhD, Stephanie Harel, MD, Lionel Karlin, MD, Damien Roosweil, Karim Belhadj, Jerome Tamburini, Arnaud Jaccard, Raphael Szalat, Bouchra Asli, MD, Marion Malphettes, MD, PhD, jean Christophe Bories, Jean Paul Fermand, MD

Blood (2012) 120 (21): 3971.

https://doi.org/10.1182/blood.V120.21.3971.3971

Published: 2012

Journal Articles

Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?

Evangelos Terpos, Meletios Athanasios Dimopoulos, MD, Stephanie Harel, MD, Francis K Buadi, M.D., Dimitrios Christoulas, Ersi Voskaridou, Efstathios Kastritis, Jean Paul Fermand, MD, Angela Dispenzieri, MD

Blood (2011) 118 (21): 806.

https://doi.org/10.1182/blood.V118.21.806.806

Published: 2011

NARROW

Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Carfilzomib-Pomalidomide-Dexamethasone in Anti-CD38 Antibodies and Lenalidomide Relapse/Refractory Multiple Myeloma: A Real Life Monocentric Cohort

Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies

Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

A Retrospective Study of 67 Inflammatory Waldenström's Macroglobulinemia

Overview of the French Practice: Therapeutic Strategies in Patient's First Relapse or Refractory Non IgM AL Amyloidosis

Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?

Therapeutic Strategies in Patients with Atypical CML (aCML) and Unclassified MDS/MPN (MDS/MPN-U). a Single Center Report

Impact Of Myelofibrosis (MF) In MDS Treated With Azacitidine (AZA). A Single Center Study

Abnormal Numbers Of Regulatory T Cell (Tregs) Subsets Are Sigificantly Associated With Adverse Disease Outcome In Lower Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Clinical and Biological Features Of Multiple Myeloma (MM) and Monoclonal Gammopathies In Patients With Human Immunodeficiency Virus (HIV) Infection

Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML)

Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents

Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only